• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine, Inc. - Common Stock (NQ:EDIT)

    2.095 -0.065 (-3.01%)
    Streaming Delayed Price Updated: 10:11 AM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 187,732
    Open 2.150
    Bid (Size) 2.090 (1,700)
    Ask (Size) 2.100 (2,100)
    Prev. Close 2.160
    Today's Range 2.073 - 2.150
    52wk Range 0.9101 - 4.537
    Shares Outstanding 81,632,619
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Editas (EDIT) Q2 2024 Earnings Call Transcript ↗
    Editas (EDIT) Q2 2024 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
    Editas Medicine beats Q3 2025 earnings estimates, reports strong revenue growth, and advances its lead gene-editing program, EDIT-401. 
    Via Chartmill

    Performance

    YTD
    +2.2%
    +2.2%
    1 Month
    -13.4%
    -13.4%
    3 Month
    -49.5%
    -49.5%
    6 Month
    -32.0%
    -32.0%
    1 Year
    +44.5%
    +44.5%

    More News

    Read More
    News headline image
    Editas Medicine Announces Third Quarter 2025 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
    Via TokenRing AI
    Topics Artificial Intelligence Climate Change Intellectual Property
    News headline image
    Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
    Via Benzinga
    News headline image
    Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗
    Via Chartmill
    News headline image
    Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
    Via Benzinga
    News headline image
    Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
    Via Benzinga
    News headline image
    Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Participate in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Why Editas Medicine Stock Was Skyrocketing This Week ↗
    Via The Motley Fool
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Top movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Wednesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗
    Via Chartmill
    News headline image
    Editas Medicine Announces Second Quarter 2025 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Can This Beaten-Down Stock Bounce Back? ↗
    Via The Motley Fool
    News headline image
    Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗
    Via The Motley Fool
    Topics Workforce
    News headline image
    2 Beaten-Down Stocks to Avoid ↗
    Via The Motley Fool
    News headline image
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
    Via Benzinga
    News headline image
    Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Editas Medicine, Inc. - Common Stock publicly traded?
    Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
    What exchange does Editas Medicine, Inc. - Common Stock trade on?
    Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
    The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
    What is the current price of Editas Medicine, Inc. - Common Stock?
    The current price of Editas Medicine, Inc. - Common Stock is 2.095
    When was Editas Medicine, Inc. - Common Stock last traded?
    The last trade of Editas Medicine, Inc. - Common Stock was at 01/08/26 10:11 AM ET
    What is the market capitalization of Editas Medicine, Inc. - Common Stock?
    The market capitalization of Editas Medicine, Inc. - Common Stock is 171.02M
    How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
    Editas Medicine, Inc. - Common Stock has 171M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.